

Department of Planning and Budget

2023 Fiscal Impact Statement

1. Bill Number: SB1084

House of Origin	<input checked="" type="checkbox"/> Introduced	<input type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
Second House	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input type="checkbox"/> Enrolled

2. Patron: Bell

3. Committee: Education and Health

4. Title: Prescription of Schedule VI controlled substances; asynchronous interactions.

5. Summary: Allows practitioners to establish a bona fide practitioner-patient relationship through asynchronous interaction for the purpose of prescribing Schedule VI controlled substances if the patient chooses not to use insurance for the encounter and if such prescribing complies with federal requirements for the practice of telemedicine. The bill directs the Board of Pharmacy to conduct a review of Schedule VI controlled substances and report to the Chairmen of the Senate Committee on Education and Health and the House Committee on Health, Welfare and Institutions by December 31, 2023, any Schedule VI substances that the General Assembly may want to consider rescheduling due to potential risk of abuse by a patient if prescribed in accordance with the standard of care for asynchronous telemedicine interactions.

6. Budget Amendment Necessary: No.

7. Fiscal Impact Estimates: Final.

8. Fiscal Implications: The provisions of this legislation would not have a fiscal impact on the Department of Health Professions.

9. Specific Agency or Political Subdivisions Affected: None.

10. Technical Amendment Necessary: No.

11. Other Comments: None.